Silver Book Fact

The rate of hospitalization from heart failure before and after transcatheter mitral valve repair (TMVR) decreases 73% (per patient year) in patients at prohibitive surgical risk.

Lim DS, Reynolds MR, Feldman T, et al. Improved Functional Status and Quality of Life in Prohibitive Surgical Risk Patients with Degenerative Mitral Regurgitation After Transcatheter Mitral Valve Repair. J Am Coll Cardiol. 2014; 64(2). https://www.ncbi.nlm.nih.gov/pubmed/24184254

Reference

Title
Improved Functional Status and Quality of Life in Prohibitive Surgical Risk Patients with Degenerative Mitral Regurgitation After Transcatheter Mitral Valve Repair
Publication
J Am Coll Cardiol
Publication Date
2014
Authors
Lim DS, Reynolds MR, Feldman T, et al
Volume & Issue
Volume 64, Issue 2
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • According to the National Institutes of Health, use of the clot-busting drug t-PA saves $4,400 per patient in hospitalization and nursing home costs.  
  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Data from clinical trials demostrate that ICDs reduce sudden cardiac death 5-10% per year for 2-3 years, compared to antiarrhythmic drugs.  
  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • According to the Pharmaceutical Research and Manufacturers of America, 146 new medicines are being developed for heart disease and stroke. They include 17 for stroke, 16 for congestive heart failure,…